Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction

Hye Jin Wang, Jae Yeo Park, Obin Kwon, Eun Yeong Choe, Chul Hoon Kim, Kyu Yeon Hur, Myung Shik Lee, Mijin Yun, Bong Soo Cha, Young Bum Kim, Hyangkyu Lee, Eun Seok Kang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Statins (HMGCR/HMG-CoA reductase [3-hydroxy-3-methylglutaryl-CoA reductase] inhibitors) are widely used to lower blood cholesterol levels but have been shown to increase the risk of type 2 diabetes mellitus. However, the molecular mechanism underlying diabetogenic effects remains to be elucidated. Here we show that statins significantly increase the expression of key gluconeogenic enzymes (such as G6PC [glucose-6-phosphatase] and PCK1 (phosphoenolpyruvate carboxykinase 1 [soluble]) in vitro and in vivo and promote hepatic glucose output. Statin treatment activates autophagic flux in HepG2 cells. Acute suppression of autophagy with lysosome inhibitors in statin treated HepG2 cells reduced gluconeogenic enzymes expression and glucose output. Importantly, the ability of statins to increase gluconeogenesis was impaired when ATG7 was deficient and BECN1 was absent, suggesting that autophagy plays a critical role in the diabetogenic effects of statins. Moreover autophagic vacuoles and gluconeogenic genes expression in the liver of diet-induced obese mice were increased by statins, ultimately leading to elevated hepatic glucose production, hyperglycemia, and insulin resistance. Together, these data demonstrate that chronic statin therapy results in insulin resistance through the activation of hepatic gluconeogenesis, which is tightly coupled to hepatic autophagy. These data further contribute to a better understanding of the diabetogenic effects of stains in the context of insulin resistance.

Original languageEnglish
Pages (from-to)2089-2101
Number of pages13
JournalAutophagy
Volume11
Issue number11
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Gluconeogenesis
Autophagy
Liver
Hydroxymethylglutaryl CoA Reductases
Insulin Resistance
Hep G2 Cells
Glucose
Obese Mice
Glucose-6-Phosphatase
Phosphoenolpyruvate
Enzymes
Vacuoles
Lysosomes
Hyperglycemia
Type 2 Diabetes Mellitus
Coloring Agents
Cholesterol
Diet
Gene Expression

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cell Biology

Cite this

Wang, Hye Jin ; Park, Jae Yeo ; Kwon, Obin ; Choe, Eun Yeong ; Kim, Chul Hoon ; Hur, Kyu Yeon ; Lee, Myung Shik ; Yun, Mijin ; Cha, Bong Soo ; Kim, Young Bum ; Lee, Hyangkyu ; Kang, Eun Seok. / Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction. In: Autophagy. 2015 ; Vol. 11, No. 11. pp. 2089-2101.
@article{f094c5e855de49ff9e4abad5f5135d4e,
title = "Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction",
abstract = "Statins (HMGCR/HMG-CoA reductase [3-hydroxy-3-methylglutaryl-CoA reductase] inhibitors) are widely used to lower blood cholesterol levels but have been shown to increase the risk of type 2 diabetes mellitus. However, the molecular mechanism underlying diabetogenic effects remains to be elucidated. Here we show that statins significantly increase the expression of key gluconeogenic enzymes (such as G6PC [glucose-6-phosphatase] and PCK1 (phosphoenolpyruvate carboxykinase 1 [soluble]) in vitro and in vivo and promote hepatic glucose output. Statin treatment activates autophagic flux in HepG2 cells. Acute suppression of autophagy with lysosome inhibitors in statin treated HepG2 cells reduced gluconeogenic enzymes expression and glucose output. Importantly, the ability of statins to increase gluconeogenesis was impaired when ATG7 was deficient and BECN1 was absent, suggesting that autophagy plays a critical role in the diabetogenic effects of statins. Moreover autophagic vacuoles and gluconeogenic genes expression in the liver of diet-induced obese mice were increased by statins, ultimately leading to elevated hepatic glucose production, hyperglycemia, and insulin resistance. Together, these data demonstrate that chronic statin therapy results in insulin resistance through the activation of hepatic gluconeogenesis, which is tightly coupled to hepatic autophagy. These data further contribute to a better understanding of the diabetogenic effects of stains in the context of insulin resistance.",
author = "Wang, {Hye Jin} and Park, {Jae Yeo} and Obin Kwon and Choe, {Eun Yeong} and Kim, {Chul Hoon} and Hur, {Kyu Yeon} and Lee, {Myung Shik} and Mijin Yun and Cha, {Bong Soo} and Kim, {Young Bum} and Hyangkyu Lee and Kang, {Eun Seok}",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/15548627.2015.1091139",
language = "English",
volume = "11",
pages = "2089--2101",
journal = "Autophagy",
issn = "1554-8627",
publisher = "Landes Bioscience",
number = "11",

}

Wang, HJ, Park, JY, Kwon, O, Choe, EY, Kim, CH, Hur, KY, Lee, MS, Yun, M, Cha, BS, Kim, YB, Lee, H & Kang, ES 2015, 'Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction', Autophagy, vol. 11, no. 11, pp. 2089-2101. https://doi.org/10.1080/15548627.2015.1091139

Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction. / Wang, Hye Jin; Park, Jae Yeo; Kwon, Obin; Choe, Eun Yeong; Kim, Chul Hoon; Hur, Kyu Yeon; Lee, Myung Shik; Yun, Mijin; Cha, Bong Soo; Kim, Young Bum; Lee, Hyangkyu; Kang, Eun Seok.

In: Autophagy, Vol. 11, No. 11, 01.01.2015, p. 2089-2101.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction

AU - Wang, Hye Jin

AU - Park, Jae Yeo

AU - Kwon, Obin

AU - Choe, Eun Yeong

AU - Kim, Chul Hoon

AU - Hur, Kyu Yeon

AU - Lee, Myung Shik

AU - Yun, Mijin

AU - Cha, Bong Soo

AU - Kim, Young Bum

AU - Lee, Hyangkyu

AU - Kang, Eun Seok

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Statins (HMGCR/HMG-CoA reductase [3-hydroxy-3-methylglutaryl-CoA reductase] inhibitors) are widely used to lower blood cholesterol levels but have been shown to increase the risk of type 2 diabetes mellitus. However, the molecular mechanism underlying diabetogenic effects remains to be elucidated. Here we show that statins significantly increase the expression of key gluconeogenic enzymes (such as G6PC [glucose-6-phosphatase] and PCK1 (phosphoenolpyruvate carboxykinase 1 [soluble]) in vitro and in vivo and promote hepatic glucose output. Statin treatment activates autophagic flux in HepG2 cells. Acute suppression of autophagy with lysosome inhibitors in statin treated HepG2 cells reduced gluconeogenic enzymes expression and glucose output. Importantly, the ability of statins to increase gluconeogenesis was impaired when ATG7 was deficient and BECN1 was absent, suggesting that autophagy plays a critical role in the diabetogenic effects of statins. Moreover autophagic vacuoles and gluconeogenic genes expression in the liver of diet-induced obese mice were increased by statins, ultimately leading to elevated hepatic glucose production, hyperglycemia, and insulin resistance. Together, these data demonstrate that chronic statin therapy results in insulin resistance through the activation of hepatic gluconeogenesis, which is tightly coupled to hepatic autophagy. These data further contribute to a better understanding of the diabetogenic effects of stains in the context of insulin resistance.

AB - Statins (HMGCR/HMG-CoA reductase [3-hydroxy-3-methylglutaryl-CoA reductase] inhibitors) are widely used to lower blood cholesterol levels but have been shown to increase the risk of type 2 diabetes mellitus. However, the molecular mechanism underlying diabetogenic effects remains to be elucidated. Here we show that statins significantly increase the expression of key gluconeogenic enzymes (such as G6PC [glucose-6-phosphatase] and PCK1 (phosphoenolpyruvate carboxykinase 1 [soluble]) in vitro and in vivo and promote hepatic glucose output. Statin treatment activates autophagic flux in HepG2 cells. Acute suppression of autophagy with lysosome inhibitors in statin treated HepG2 cells reduced gluconeogenic enzymes expression and glucose output. Importantly, the ability of statins to increase gluconeogenesis was impaired when ATG7 was deficient and BECN1 was absent, suggesting that autophagy plays a critical role in the diabetogenic effects of statins. Moreover autophagic vacuoles and gluconeogenic genes expression in the liver of diet-induced obese mice were increased by statins, ultimately leading to elevated hepatic glucose production, hyperglycemia, and insulin resistance. Together, these data demonstrate that chronic statin therapy results in insulin resistance through the activation of hepatic gluconeogenesis, which is tightly coupled to hepatic autophagy. These data further contribute to a better understanding of the diabetogenic effects of stains in the context of insulin resistance.

UR - http://www.scopus.com/inward/record.url?scp=84964265098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964265098&partnerID=8YFLogxK

U2 - 10.1080/15548627.2015.1091139

DO - 10.1080/15548627.2015.1091139

M3 - Article

VL - 11

SP - 2089

EP - 2101

JO - Autophagy

JF - Autophagy

SN - 1554-8627

IS - 11

ER -